Inmed pharmaceuticals reports full year fiscal 2023 financial results and provides business update

Completed phase 2 clinical trial demonstrating anti-itch activity of inm-755 (cbn) topical cream $4.1m revenues in fiscal year 2023, representing a 280% increase over the previous fiscal year and $2.3m revenues in fiscal q4 2023, representing 123% increase quarter over quarter ("qoq") strengthens pharmaceutical pipeline with launch of inm-900 series program targeting neurodegenerative diseases such as alzheimer's vancouver, british columbia--(newsfile corp. - september 29, 2023) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the fiscal year ending june 30, 2023 and provided a business update on the pharmaceutical drug development programs as well as the commercial segment for a wholly-owned subsidiary, baymedica, llc ("baymedica"). the company's full financial statements and related md&a for the fiscal year ended june 30, 2023, are available at www.inmedpharma.com and at www.sedarplus.ca.
INM Ratings Summary
INM Quant Ranking